Radiopharmaceutical developer Navidea Biopharmaceuticals has received a five-year patent extension for its Lymphoseek radiopharmaceutical.
The U.S. Patent and Trademark Office has extended the duration of U.S. patent No. 6,409,990 until May 12, 2025, according to Navidea.
The patent covers the technology behind Lymphoseek, a technetium-based radiopharmaceutical that has been licensed to Cardinal Health. The extension allows Cardinal Health and Navidea to extend their exclusive rights to manufacture and commercialize Lymphoseek until the end of the extended patent date, according to the company.
